stem cells diabetes

Weekly reads: cancer stem cells & other pubs plus a puzzler

kyu yum nature cancer stem cells niche

Cancer stem cells are one of the most interesting areas of research, intersecting the stem cell and cancer fields. Today’s weekly reads post highlights some new cancer stem cell articles along with some other interesting papers. I also note a recent weak stem cell clinical trial paper that is not a recommended read but is …

Weekly reads: cancer stem cells & other pubs plus a puzzler Read More »

Weekly recommended science reads: stem cells, CRISPR, cancer & more

CRISPR-for-muscular-dystrophy.-Zhang-et-al.-Science-2020.-Screenshot-of-Fig.-2-featured-image

There’s never enough time to get all of one’s science reading done, but we can try! It helps to have a list of “to-read” articles, whether actual research articles or media pieces. In the old days, I remember my mentors saying they literally had “piles” of journal articles on their coffee tables, bathrooms, bedrooms, etc. …

Weekly recommended science reads: stem cells, CRISPR, cancer & more Read More »

7-Year Glitch? Updates on my overly optimistic 2013 stem cell predictions for 2020

STEM-CELL-PREDICTIONS

Back in 2013, a half dozen years ago, I went out on a limb and made predictions for the stem cell field for 2020. These are different than my yearly predictions for the coming year (for instance, you can see my predictions made in 2018 for this year of 2019 here). As to my 2013 …

7-Year Glitch? Updates on my overly optimistic 2013 stem cell predictions for 2020 Read More »

Quick Q&A with ViaCyte CEO on CRISPR-stem cell work

VC-01-post-implant-final1-e1503703572933, viacyte

We heard this week about the encouraging news of a new CRISPR-stem cell collaboration between stem cell biotech ViaCyte and CRISPR Therapeutics. The goal of the team is to make genetically engineered pancreatic derivatives from stem cells that would have a unique immune stealthiness. If such an approach was successful, patients would not need to …

Quick Q&A with ViaCyte CEO on CRISPR-stem cell work Read More »

ViaCyte & CRISPR Therapeutics team up to battle diabetes

ViaCyte

What happens when one of the most exciting stem cell biotechs ViaCyte teams up with a firm like CRISPR Therapeutics to use a combination of gene editing and cell therapy? Hopefully a synergistic partnership emerges that in this case can develop an effective stem cell-based therapy for diabetes. You can see a press release on …

ViaCyte & CRISPR Therapeutics team up to battle diabetes Read More »

ViaCyte Interview on Diabetes Stem Cell Trials & Cool Role of Gore-Tex Tech

ViaCyte

When I think of the promise of stem cells for diabetes, the privately held California stem cell firm ViaCyte is the first biotech that comes to mind now. It has promising stem cell clinical trial work building. Today’s post is a new interview with the company’s CEO Paul Laikind. For past posts on ViaCyte see here, which …

ViaCyte Interview on Diabetes Stem Cell Trials & Cool Role of Gore-Tex Tech Read More »

Stem cell good news: Spinal Cord Injury Trial, CIRM, Grants, & More

Jan-Nolta-stem-cell-good-news-2

Stem cell good news time…and more will be coming later this week. The stem cell and regenerative medicine world sometimes feels chaotic because so much is going on both on the positive and negative sides of things. There is a whirlwind of activity and developments, and a tendency sometimes within our arena to just avoid …

Stem cell good news: Spinal Cord Injury Trial, CIRM, Grants, & More Read More »

Stem cell therapy review of good news: UC Davis, Asterias, Cynata, Mesoblast, ViaCyte

VC-01-post-implant-final1-e1503703572933, viacyte

It’s a difficult, but very important road to conclusively prove that an investigational stem cell therapy is both safe and effective in order to get final approval FDA or equivalents in other countries. For this reason, it is beneficial to highlight even small, but positive steps forward including encouraging pre-clinical data. Today I’m doing a …

Stem cell therapy review of good news: UC Davis, Asterias, Cynata, Mesoblast, ViaCyte Read More »

Burt Northwestern Stem Cell MS Trial Part 2: Marketing ‘Cure’-Like Outcomes?

stem-cells-MS-Northwestern-University

Can science now cure MS in some patients with stem cells or is that near on the horizon? What about stem cells for other serious autoimmune disorders? What are the risks to patients in terms of health, money, and hope? What if patients must find $100,000 or $200,000 just to get into a clinical trial for …

Burt Northwestern Stem Cell MS Trial Part 2: Marketing ‘Cure’-Like Outcomes? Read More »